Search results
Showing 3301 to 3315 of 7691 results
The Commercial Liaison Team (CLT) works with companies who are considering a patient access scheme for their drug or treatment. Patient access schemes
Role and responsibilities of the National Institute of Health and Care Excellence
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
Decision aid for Intrabeam radiotherapy system for adjuvant treatment of early breast cancer, TA501 c NICE 2018. All rights reserved. Subject to...
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
NICE Advice is an advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market, and supporting organisations who fund or generate evidence for health technologies.
How we collect and use your personal information, and your rights under data protection legislation
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
Find out more about the progress made in implementing NICE guidance on diagnostic pathology
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals. Read the appeal panel
NICE transparency of spend
Our publication scheme lists all of the information we routinely make available, and where you can find it. We publish most of the information below...
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members